ScreenerHero

CAMP CAMP4 THERAPEUTICS CORPORATION

NAS · US · Healthcare · Biotechnology · camp4tx.com
3.840USD-3.03%Mkt Cap: 240.97M $P/E: —

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap240.97M USD
Enterprise Value164.48M USD
Revenue (TTM)4.22M USD
Gross Profit-34.47M USD
Net Income (TTM)-80.40M USD
Revenue/Share0.09 USD
Last Price3.840 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees48
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.90
PEG—
EV/EBITDA-3.25
EV/Revenue39.01
P/S58.94
P/B-304.62
EPS (TTM)-2.32
EPS (Forward)-0.81
52W Range
2.86020% of range7.750
52W High7.750 USD
52W Low2.860 USD
Profitability
Gross Margin0.00%
Oper. Margin-752.11%
EBITDA Margin0.00%
Profit Margin-2298.54%
ROE-168.55%
ROA-68.25%
Growth
Revenue Growth18.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.55M USD
CapEx (TTM)279.00K USD
FCF Margin-304.27%
FCF Yield-5.32%
Net Debt-84.03M USD
Net Debt/EBITDA1.66
Balance Sheet
Debt/Equity0.04
Current Ratio4.70
Quick Ratio4.53
Book Value/Sh-0.01 USD
Cash/Share1.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.57 USD
Upside (mean)+175.3%
Target Range6.000 USD – 15.00 USD
6.000+175.3% to mean15.00
# Analysts7
Ownership
Shares Out.62.75M
Float43.33M
Insiders9.65%
Institutions79.74%
Short Interest
Short Ratio3.5d
Short % Float2.16%
Short % Out.1.58%
Shares Short992.71K
Short (prev mo.)1.28M
Technical
SMA 504.151 (-7.5%)
SMA 2004.464 (-14.0%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)351.07K
Avg Vol (10d)316.51K
Technical Indicators
RSI (14)44.1
MACD-0.0759
MACD Signal-0.0724
MACD Hist.-0.0036
BB Upper4.374 USD
BB Middle4.021 USD
BB Lower3.667 USD
BB Width17.58%
ATR (14)0.3375 USD
Vol Ratio (20d)0.43x